Member Info for equitrder

FULL DESCRIPTION Amryt Pharma plc, formerly Fastnet Equity plc, is a United Kingdom-based specialty pharmaceutical company. The Company focuses on developing and delivering treatments for patients with rare and orphan diseases. The Company’s products include Episalvan and Imlan. The Company’s products focus on developing somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases, including acromegaly and Cushing's disease. The Company’s Episalvan is a prescription pharmaceutical product, which accelerates wound healing. The Company’s Episalvan consists of two ingredients, such as betulin-based active ingredient and sunflower oil as the excipient. The Company's Imlan products have regenerative and anti-inflammatory properties. Betulin is the active ingredient in the Imlan products and functions as the stabilizer of the creams and lotions. The Company’s Imlan Creme Pur consists of Betulin, oil and water ingredients.» Full Overview of AMYT.L

Looks like we have ran out of spinach ...

16:23:56 20.90 50,000 Why is it not reflected in the closing price?

Every time(one exception)the Fed were 'supposed' to be raising interest rates over the last 4 years they crashed the stock market. Collusion?? Where is the inflation??? New Economic 101??? Trickle down dead??(: Reagan is the hero of the so called deplorables. Trump and his band of merry geriatric billionaires are only interested in 1 thing and thats lining their own pockets.unless they are repenting for their sins of the past and are looking to buy indulgences for their salvation...

Dino what t are you trying to say? Yes we know Aegerion had crappy sales in europe and are now outsourcing.The Chief Medical Officer at Amryt was involved in the FDA approval of Lojuxta so he knows the drug. Maybe Amyrt can market it in a different way.

John let me it this to you. A 10% drop in equities will control inflation. (: A lot more manageable than adjusting interest rates or decreasing money supply.

Are flocking to Italy. They will drive price down to get the best deal. Right now the write downs are about 50% looks like they want 20% which will bankrupt the country. We are all told to be worried about Russia and China its the American locusts that are the problem whether it be financial or their war mongering.

Yep Shrew agree 100% was just reading up on Aegerion.They do know the product. I can't get the the pricing for Lojuxta but it ain't cheap.I'm seeing some pricing of £17k for treatment.Don't quote me on that. Hey your moving up in my world (:

John I know 3 small businesses who raised money thru crowd funding because the banks wouldn't get involved. It still hasn't been properly regulated but imo it will be how your average Joe Soap will earn his returns in the future.

Interest rates will never rise again. 1. because sovereigns have too much debt. 2.Why should you be rewarded for leaving money sitting on deposit in a bank?

Nope I'm pretty happy actually I have a boatload of Amryt Pharmaceutical

We will see Bruce the Italian banks seem to be turning down again.

What the f... are you talking about the stock was a .195 2 day ago!!!!!

Well Observe that's your observation personally i see a car crash. Austria was not a pro EU winner.This far right party only won 20%of the vote in the last election and its a ceremonial position. As for Mario is he weren't buying sovereigns Italy Spain Portugal and Ireland wouldn't be able to fund their budgets their cost of funds would be so high

Bruce the results of the referendum were a lot wider than expected. I think this is a B.S. rally and there will be protests and shutdowns if another caretaker is appointed especially the finance minister. Then again they did vote Berlusconi in for years so I guess they deserve what they get

Far right was never going to win in Austria .. Polls were all wrong!!! Le Pen will never win in France either she is too polarized. What is scary is that 46% of Austrians support a Nazi sympathizer.

18-19.5 very wide The mm's surely can't be short shares already??

I'm not getting this rally. The referendum was annihilated and I don't think the people will allow a caretaker lame duck to take over for the next 18 months. When is the president of Italy up for election because he could be out on his ear as well.

Cont.... ...destined for the mass market. As they are niche areas where there are no current treatments, firms are often allowed to charge more for a breakthrough new product. Around 19% of all prescriptions are for these rare ailments, and the market globally is estimated to be worth US$176bn. One of their other products AP102, acquired from from Som has a $1.2bn market. 3. Management Harry Stratford – Non-executive Chairman Harry Statford Harry has over 40 years’ experience in the pharmaceutical industry and has built two successful publicly listed pharmaceutical companies. Mr Stratford founded Shire Plc in 1986 and was CEO for almost a decade. Shire Plc grew from humble beginnings to be one of Europe’s largest specialty pharmaceutical companies and its stock is a constituent of the FTSE100 index. Mr Stratford then went on to be founder, CEO and Executive Chairman of Prostrakan Plc, another international specialty pharmaceutical company, which was subsequently acquired by Kyowa Hakko Kirin of Japan for £292m in 2011. Amryt’s strategy is very similar to that of Shire. Stratford pioneered this approach as founder of Shire, the world’s largest speciality pharma company. Joe Wiley – Chief Executive Officer JOE WILEY Founder of Amryt Pharma. Trained in general medicine at Trinity College Dublin, specialising in neurology, and is a member of the Royal College of Physicians in Ireland. MBA from INSEAD. Over 20 years’ experience in medical, pharmaceutical (with Astellas Pharma) and venture capital industries, opening and leading Sofinnova Ventures’ European office. Rory Nealon – CFO/COO Rory Nealon Rory is a qualified chartered accountant with over 15 years’ experience at CFO/COO level in listed businesses, 13 of which are in the healthcare industry. Ray Stafford – Non-Executive Director Ray Stafford Ray Stafford was previously Executive Vice President of Global Marketing for Forest Laboratories which was listed on NYSE prior to being acquired for c. $28bn. Michele Bellandi – Chief Commercial Officer Michele Bellandi Mr Bellandi has over 20 years’ experience in the pharmaceuticals industry with a focus on specialty and rare diseases. He was most recently the Head of Commercial Europe for Shire where he was responsible for the entire portfolio representing over US$1 billion in revenues and 600 employees.

3 reasons I Bought More Shares in Amryt Pharma (AMYT) This Week Current Share Price: 14.75p Market Cap: £30.73m Share in Issue: 208m (approximately 65% are held by shareholder with 3% or more). Cash: €12.6m (or £10.75m, as of 31st December 2015) About Amryt Pharma AMYT Amryt Pharma was admitted to AIM on 19th April 2016 following the reverse takeover of Fastnet Equity (FAST). Amryt’s lead product, Episalvan®, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to further develop Episalvan® as a new treatment for a hereditary skin disorder called Epidermolysis Bullosa in both Europe and the U.S. Amryt’s earlier stage products are focussed on developing novel, next generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is high unmet medical needs. These include acromegaly and Cushing’s disease. 3 reasons I Bought More Shares in Amryt Pharma (AMYT) This Week 1. The Share Price AMYT CHART Amryt’s share price is at an all time low. When Amryt Pharma was admitted to AIM following the takeover of Fastnet Equity, they raised £10m at 24p. The share price is currently 14p. This is post consolidation, of 1 for 8 shares, so this would’ve been 1.84p when it was Fastnet Equity.You couldn’t have bought Fastnet shares at 1.84p and remember, this was when it was a failing oil & gas explorer/ producer. Now as Amryt Pharma, they’ve acquired two drug assets, Episalvan from Birken a relatively de-risked asset targeted at a rare childhood disease that causes severe skin conditions and AP102 from Som which is focused on acromegaly/Cushing’s disease. Plus they have £10m in cash (as of 31st December 2015) and a very experienced board of directors with a clear strategy. Their strategy is to acquire and develop more orphan drug assets that target significant commercial opportunities to create a Specialty Pharma company. The acquisitions of Birken and Som are the first steps in delivering this strategy and others are likely to follow as and when appropriate. Amryt has an EV of £22m compared to six quoted peers trading on a range of £48m (Phase 1 assets) to £1,608m (Phase III). This seems to suggest that there is considerable upside potential in Amryt’s Phase II/III assets. Mergers and acquisitions activity also underline the fact that Amryt is undervalued. M&A activity for similar assets are in the range $97-$842m. 2. Potential Penny Stock Potential Episalvan, acquired from Birken has been awarded orphan drug designation (ODD) in the US and the EU for EB, and the market for this indication alone is estimated to be US$1.5bn. Orphan designation often means the product can be fast-tracked – usually at a fraction of the cost of developing medication